EP0985052B1 - Methods and compositions to identify swine genetically resistant to f18 e. coli associated diseases - Google Patents
Methods and compositions to identify swine genetically resistant to f18 e. coli associated diseases Download PDFInfo
- Publication number
- EP0985052B1 EP0985052B1 EP98923570A EP98923570A EP0985052B1 EP 0985052 B1 EP0985052 B1 EP 0985052B1 EP 98923570 A EP98923570 A EP 98923570A EP 98923570 A EP98923570 A EP 98923570A EP 0985052 B1 EP0985052 B1 EP 0985052B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- swine
- coli
- resistant
- gene
- fucosyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 94
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 19
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title abstract description 6
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 claims abstract description 40
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 claims abstract description 29
- 239000002773 nucleotide Substances 0.000 claims abstract description 22
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 22
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 22
- 238000003556 assay Methods 0.000 claims abstract description 14
- 208000028774 intestinal disease Diseases 0.000 claims abstract description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 32
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 14
- 229930024421 Adenine Natural products 0.000 claims description 11
- 229960000643 adenine Drugs 0.000 claims description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 11
- 238000003752 polymerase chain reaction Methods 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 101150084750 1 gene Proteins 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 108010019236 Fucosyltransferases Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 102000006471 Fucosyltransferases Human genes 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102100039835 Galactoside alpha-(1,2)-fucosyltransferase 1 Human genes 0.000 abstract description 50
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 241000282887 Suidae Species 0.000 abstract description 23
- 206010030113 Oedema Diseases 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 10
- 206010012735 Diarrhoea Diseases 0.000 abstract description 8
- 108010079306 galactoside 2-alpha-L-fucosyltransferase Proteins 0.000 abstract description 8
- 238000006467 substitution reaction Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 30
- 108700026244 Open Reading Frames Proteins 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 241000255969 Pieris brassicae Species 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 230000001488 breeding effect Effects 0.000 description 12
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000009395 breeding Methods 0.000 description 10
- 244000144980 herd Species 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 101150048676 FUT1 gene Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 8
- 229960003132 halothane Drugs 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 102000042094 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 description 7
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 5
- 208000035240 Disease Resistance Diseases 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 101150010169 FUT2 gene Proteins 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000031864 metaphase Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100227969 Homo sapiens FUT1 gene Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009582 blood typing Methods 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CXENHBSYCFFKJS-OXYODPPFSA-N (Z,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(\C)C=C CXENHBSYCFFKJS-OXYODPPFSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100033326 Alpha-1B-glycoprotein Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 210000001224 bacterial fimbriae Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012254 genetic linkage analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000001537 mesocolon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- compositions and non-invasive methods are provided for the identification of swine genetically resistant to E. coli related diseases, in particular, intestinal diseases associated with a strain of E. coli bacteria supplied with fimbriae F18.
- DNA polymorphisms in swine alpha (1,2) fucosyltransferase ( FUT1 ) gene were identified that differentiate resistant from susceptible swine and provide a diagnostic test useful for swine breeders.
- a major problem in breeding swine is to keep them disease-free. Intestinal disorders post weaning are a particular problem.
- a limited number of serotypes of toxigenic Ecsherichia (E.) coli strains are the causative agents of oedema disease and postweaning diarrhea in swine which induce serious economic losses, especially among piglets aged 4 to 12 weeks, in swine breeding farms all over the world.
- the typical clinical symptoms of oedema disease are neuroiogical signs such as ataxia, convulsions and paralysis.
- oedema is typically present at characteristic sites such as eyelids and forehead, stomach wall and mesocolon.
- the diseases are caused by Shiga-like toxin-II variant and enterotoxins LT, STa, STb, respectively, produced by E. coli that colonize the surface of the small intestine without affecting major morphological changes of the emerocytes (cells in the intestine).
- Certain types of bacterial E. coli strains, F18, F4 (K88) are major, lethal villains in this regard.
- "Oedema disease of pigs is an enterotoxaemia characterized by generalized vascular damage. The latter is caused by a toxin. Shiga-like toxin-II variant, produced by certain strains of E. coli .” (Bertschinger et al ., 1993).
- the E. coli are distinguished by their pili types.
- a group of adhesive fimbriae that are related are designated e.g ., K88 or F18 (Vögeli et al ., 1997).
- ECF18R coli F18-receptor
- SSC6 porcine chromosome 6
- HAL halothane linkage group on chromosome 6.
- the receptor for K88 E. coli is on chromosome 13.
- the mechanism for resistance appears to be that intestinal borders in resistant animals are not colonized by E. coli, i.e ., the bacteria do not adhere to intestinal walls of resistant swine. Glycoprotein receptors in the brush border membrane of the intestine were shown to be responsible for the differences between adhesive and non-adhesive phenotypes related to some E. coli , therefore, the genotype of the host swine determines resistance.
- the fimbriated bacteria also have been studied (WO 9413811).
- a genetic "marker" locus is a coding or non-coding locus that is close to a genetic locus if interest, but is not necessarily The locus itself. Detectable phenotypes include continuous or discontinuous traits, e.g. restriction length fragment polymorphisms, production traits, bacterial adhesion traits, colorimetric or enzymatic reactions, and antibiotic resistance.
- the S locus controls expression of The A and 0 blood group antigens. Swine homozygous recessive at the S locus do not express either A or 0 blood antigens.
- the blood group H and Se loci have been mapped genetically and physically to human chromosome 19q13.3. This region is evolutionarily conserved, containing genes homologous to the HAL linkage group of genes in pigs.
- the blood group H encoding gene is the so called FUT1 whereas the Se gene is equivalent to the FUT2 gene.
- FUT1 determines H antigen expression in the erythroid cell lineage, whereas FUT2 regulates expression of the H antigen in the secretory epithelia and saliva.
- Conservation of the FUT1 gene has been shown in lower mammals such as rat and rabbit, and The mRNA expression has been shown in rabbit brain tissue and rat colon.
- blood groups and E. coli swine diseases include that carbohydrate structures of blood group antigens mediate the adhesion of some pathogenic microorganisms to host tissues, e.g. Heliobacter pylori adhere to Lewis b blood group antigens, and E. coli causing urinary tract infections adhere to blood group P substance.
- Genes encoding glycosyltransferases that are responsible for the formation of the blood group specific carbohydrate structures therefore, represent candidate genes for the control of bacterial colonization by the host. The localization of these genes is in the same chromosomal region as The locus responsible for adhesion/non-adhesion of F18 positive E. coli in The swine small intestine. Swine do not express blood group antigens A and 0 until after weaning, this is The same time that they become susceptible to disease caused by F18 E. coli .
- compositions and non-invasive methods of the present invention provide detection and elimination of swine that are susceptible to E. coli associated diseases.
- a non-invasive method for identifying a swine that is resistant to intestinal colonization by E. coli F18 includes the following steps: determining whether a genetic polymorphism associated with resistance tto colonization is in a biological sample from the swine; and inferring that the swine is resistant if the swine is homozygous for the polymorphism 1 .
- the method is determining in a biological sample from the swine whether the nitrogen base at position 307 in the alpha (1,2) fucosyltransferase gene of the swine is only adenine or has guanine; and identifying the swine as resistant if the only nitrogen base at position 307 is adenine.
- restriction fragment length polymorphisms are analyzed on a gel that separates them by molecular weight.
- Restriction endonucleases are enzymes that reproducibly cut nucleic acid molecules at specific sites, resulting in nucleic acid fragments of different molecular weights, depending on the locations of the cuts.
- the invention also relates to a method for breeding swine resistant to E. coli associated diseases by selecting for breeding swine that have a genetic polymorphism in the alpha (1,2) fucosyltransferase 1 gene that identifies them as swine that are resistant to E. coli related diseases; and breeding the selected swine.
- An aspect of the invention is a DNA molecule which is polymorphic for the alpha (1,2) fucosyltransferase 1 gene in swine, in particular a sequence in accordance with FIG. 1.
- Other aspects of the invention are molecules with nucleotide sequences complementary to that of FIG. 1, and polymorphic at resistance producing nucleotide positions.
- An aspect of the invention is an isolated DNA molecule with a substitution of adenine for guanine in position 307. This molecule may also have a substitution adenine for guanine in position 857.
- Other isolated DNA molecules of the present invention include those with a mutation at nucleotide position 229 of the sequence of FIG. 1, wherein the codon CTT is changed to TTT, encoding for the amino acid phenylalanine instead of leucine.
- a mutation at nucleotide position 714 is from GAT ⁇ GAC, but there is no accompanying amino acid substitution in the encoded product.
- Polypeptides encoded by the DNA molecules of the present invention and having alpha (1,2) fucosvltransferase activity are also aspects of the invention.
- a molecular assay for detecting E. coli F18 receptors in swine is to (a) isolate DNA from porcine nucleated cells; (b) amplify the DNA in a polymerase chain reaction (PCR) using oligonucleotides as primers which are complementary to a DNA sequence of the porcine alpha (1,2) fucosyltransferase gene 1; (c) perform a restriction enzyme digest with at least one restriction enzyme e.g ., CfoI; (d) separate the resulting fragments by gel electrophoresis; and (e) determine the respective numbers and lengths of fragments on the gel; and (f) determine from the numbers and lengths of fragments of FUT1 , which F18 receptor genotype is present in the porcine cells.
- PCR polymerase chain reaction
- RFLP restriction length polymorphism analysis
- a kit for detecting polymorphisms associated with E. coli F18 receptors uses oligonucleotides in separate containers which are complementary to a DNA sequence of the porcine alpha (1,2) fucosyltransferase gene 1 that distinguishes resistant from sensitive swine. The test can be performed on swine of any age.
- the polymorphisms are also useful to develop drugs to treat swine that have E. coli -associated disease.
- a mutated form of porcine alpha (1,2) fucosyltransferase could interfere with the normal enzyme, preventing it from producing the intestinal receptor for F18.
- FIG. 1 show the nucleotide sequence ( FUT1 ) (below) and the predicted amino acid sequence (above) of the swine ⁇ 1 ⁇ 2 fucosyltransferase polymorphism of the present invention using the one-letter amino acide code.
- Resistant pigs differ from sensitive pigs at the E. coli F18 receptor locus as identified by the polymorphic markers of the present invention.
- the present invention provides non-invasive methods and compositions to distinguish with a high level of sensitivity and specificity, swine that are genetically susceptible to diseases associated with F18 E. coli infection from resistant swine.
- a DNA polymorphism in the alpha (1.2) fucosyltransferase ( FUT1 ) gene was identified that differentiates resistant from susceptible swine.
- the polymorphism arose by a mutation (change) in a nucleotide sequence leading to a new allele.
- An allele is a condition of a gene. In a population there may be many alleles of a gene differing by nitrogen base substitutions, presumably caused by mutations in an ancestral DNA molecule.
- the coexistence in a population of more than one allele is called a genetic polymorphism.
- Loci at which more than one allele may exist as apparently stable components of a population is a polymorphic locus.
- one of the polymorphic loci is at a low frequency in the population.
- the resistant swine As determined from a biological sample, preferably blood, the resistant swine have a polymorphism in their genomes in which the only base detected at position 307 (see FIG. 1) in the nucleotide sequence is adenine, whereas the base in the same position in homozygous susceptible swine is guanine. Heterozygous swine will show both types of DNA and will be susceptible.
- the polymorphism is a variation of a porcine gene sequence reported by Cohney et al ., 1996.
- polymorphisms have been found in the alpha (1,2) fucosyltransferase 1 gene ( FUT1 ).
- FUT1 fucosyltransferase 1 gene
- a polymorphism that has a single nucleotide base substitution at position 307 was used to establish a close linkage between the fucosyltransferase gene and the S -system, the ECF18R locus and other loci of the HAL linkage group.
- the detection of the close linkage of the mutation at FUT1 and ECF18R allowed a molecular test to be developed for the identification of E. coli F18 adhesion resistant, heterozygous (carrier) and homozygous susceptible pigs.
- This diagnostic test identifies, with high sensitivity and specificity, pigs that are susceptible to oedema disease and postweaning diarrhea.
- the incidence of the polymorphisms of the present invention differs among swine breeds. Vögeli, et a. (1997) presented frequencies of the M307 allele in 5 pig breeds from herds that were not related to one another.
- the availability of the diagnostic test for the polymorphism of the present invention provides breeders with the opportunity to effectively eliminate the ECF18R susceptible allele from their swine herds, thereby eliminating a prerequisite for E. coli F18 bacterial causing oedema disease and postweaning diarrhea.
- the present invention further includes nucleotide sequences that are variants of a sequence of the alpha (1,2) fucosyltransferase gene 1 representing the various polymorphisms at bp 307, and diagnostic molecular based kits to identif, polymorphisms in the alpha (1,2) fucosyltransferase gene.
- ECF18R E. coli F18 receptor locus 5 cosmids and one genomic clone containing the gene were isolated containing the alpha (1,2) fucosyltransferase genes, FUT1 and FUT2 (Meijerink et al ., 1997), from a porcine genomic library. Mapping by fluorescence in situ hybridization placed all these clones in band q11 of porcine chromosome 6 (SSC6q11).
- the nucleotide positions are numbered from ATG (encoding methionine).
- the open reading frame (ORF) extends from there to the terminating codon, that is 1098 nucleotides in length. Nucleotides before and after this ORF may vary, e.g . as in FIG. 1.
- Analysis of these mutations in 34 matings of Landrace families with 221 progeny showed close linkage with locus controllling resistance and susceptibility to E. coli F18 adhesion and colonization in the small intestine ( ECP18R ) and with the locus of the blood group inhibitor S . Therefore, the M307 nutation is a good marker for marker-assisted selection of E. coli F18 adhesion resistant animals.
- the polymorphisms of the present invention are easily identified using PCR-RFLP tests.
- One embodiment of the tests used a 160bp fragment of porcine alpha (1,2) fucosyltransferase 1 amplified using PCR with the following primers: 5'CCAACGCCTCCGATTCCTGT3' and 5'GTGCATGGCAGGCTGGATGA3' (Table 1).
- Preferred PCR conditions for this embodiment are 25 cycles at the following times and temperatures: 94°C, 30 sec; 60°C, 45 sec; 72°C, 90 sec.
- the amplified DNA from resistant swine was digested by the restriction enzyme Hgal, but was not digested by the restriction enzyme HinPI.
- the amplified DNA from homozygous susceptible swine was digested by the restriction enzyme HinPI.
- the amplified DNA from heterozygous susceptible swine was partially digested by both enzymes.
- DNA was isolated from porcine nucleated cells according to standard procedures.
- Direct sequencing of porcine FUT1 and FUT2 sequences and their flanking regions in animals of different ECF18R genotype (Bb, bb) resulted in the identification of two G ⁇ A transitions at positions 307 and 857 (termed M307 and M857 , respectively) of FUT1 ORF.
- the M307 transition eliminates a restriction site for CfoI.
- Amplification of DNA isolated from porcine nucleated cells was performed according to standard procedures with primers P6 and P11 (3 min at 95°C, 30 cycles of 30 sec at 95°C, 30 sec at 56°C and 30 sec at 72°C, followed by a 7 min final extension at 72°C) followed by CfoI digestion and separation on a 3% agarose gel resulted in a restriction fragment length polymorphism (RFLP).
- RFLP restriction fragment length polymorphism
- Example 2 Sensitivity and Specificity of an Assay using Alpha (1,2) Fucosyltransferase in Detecting Swine Resistant to F18 E. coli
- Intestinal cells were purified by scraping the mucosal surface off the intestine, lysing the cells in a hypotonic EDTA solution and washing by centrifugation. The purified intestinal cell brush borders were incubated with F18 E. coli . This mixture was examined by phase contrast microscopy. This assay determined if swine were susceptible (intestinal samples had adhering bacteria) or resistant (intestinal samples had no adhering bacteria). The PCR-RFLP assay for the polymorphism correlated with the bacteria-intestinal cell binding assay in 53 of 53 resistant swine and 128 of 130 susceptible swine.
- Two swine that were determined susceptible using the bacteria-intestinal cell binding assay were incorrectly predicted to be resistant using the PCR-RFLP assay.
- Two of the six herds examined contained resistant pigs, while only one herd had porcine stress syndrome, demonstrating that the PCR-RFLP assay can identify disease resistant animals in animals that do not have porcine stress syndrome.
- Cosmids ETHs1, -s2, -s3, -s4 and -s6 were identified after screening of the cosmid library with a FUT1 nucleotide probe obtained from porcine genomic DNA with primers P7 and P10 and were mapped by FISH and DISC-PCR to chromosome 6 in band q 11.
- cosmid ETHs2 KspI subclones 940 bp and 6.2 kb in length were isolated, corresponding to the estimated length of hybriding KspI fragments on the Southern blot. The sequence results of both subclones were combined to yield a 1501 bp sequence, which was in agreement with results of direct sequencing of genomic PCR products.
- the 1501 bp sequence contains an open reading frame (ORF) of 1098 bp corresponding to the human FUT1 ORF, with 82.3% nucleotide and 80.8% amino acid identity.
- the ORF encodes a polypeptide.
- Example 5 Identification fo a Porcine FUT2 and a Pseudogene FUTP
- ETHs1 has one DNA fragment (2.7 kb) that hybridizes to FUT1 sequences, whereas ETHs3 has two (2.7 kb and 8.2 kb).
- ETHs3 has two (2.7 kb and 8.2 kb).
- Subcloning and partial sequencing of the 2.7 kb EcoR1 fragment of ETHs1 and -s3 confirmed that these two fragments are identifcal.
- the sequence is highly similar to the human FUT2 but shows several changes in the NH 2 and -COOH terminal regions. These changes lead to frame shifts that are not compatible with a conserved ORF, therefore an assumption is that the sequence obtained from the 2.7 kb fragment represents a pseudogene ( FUT2P ).
- the sequence of the subclones obtaiend represents a 1023 bp ORF and is 85% identical at the nucleotide- and 83% identical at the amino acid level to the human FUT2 sequence. Many differences in the NH 2 and -COOH terminal regions were observed between the porcine FUT2 sequence and the FUT2P sequence derived from the 2.7 kb fragment.
- the predicted amino acid sequence corresponds to the partially determined amino acid sequence of the porcine Secretor enzymes (Thurin and Blaszcyk-Thurin. 1995).
- the porcine FUT1, FUT2 and FUTP sequences obtained were submitted to GenBank and have accession numbers U70883, U70881 and U70882, respectively.
- the FUT1 and FUT2 genes have highly homologous sequences. This has to be considered in, for example, primer development. Furthermore, FUT1 and FUT2 enzyme activity need to be differentiated in further studies.
- DNA was isolated from porcine nuclated cells according to standard procedures. Direct sequencing of porcine FUT1 and FUT2 sequences and their flanking regions in animals of different ECF18R genotypes ( Bb, bb ) resulted in the iedntification of two G-A transitions at positions 307 and 857 (termed M307 and M857 , respectively) of the FUT1 ORF.
- the M307 transition eliminates a restriction site for the enzyme CfoI.
- Amplification of DNA isolated from porcine nucleated cells was performed according to standard procedures with primers P6 and P11 (3 min at 95°C, 30 cycles of 30 sec at 95°C, 30 sec at 56°C and 30 sec at 72°C, followed by a 7 min final extension at 72°C) followed by CfoI digestion and separation on a 3% agarose gel resulted in a restriction fragment length polymorphism (RFLP).
- RFLP restriction fragment length polymorphism
- the M857 mutation is a transition that eliminates an AciI site.
- Primer PBEST was designed to mismatch two additional AciI sites at positions 866 and 872.
- PCR with primers P7 and PBEST (3 min. at 95°C, 30 cycles of 30 sec at 95°C, 30 sec at 56°C and 30 sec at 72°C, followed by a 7 min final extension at 72°C) followed by AciI digestion enables PCR-RFLP analysis on a 3% agarose gel.
- Homozygous M857 AA animals show a 174 bp fragment while amplification products of M857 GG animals show 136- and 38- bp fragments.
- ECF18R b the oedema and postweaning diarrhea resistance allele
- ECF18R B the oedema and postweaning diarrhea susceptibility allele
- Table 4 shows that the distribution of FUT1 genotypes at nucleotide position 307 among ECF18R types was significantly different from the expected ratio under a hypothesis that the two are independent.
- 118 were determined to have the genotype M307 A / A in the DNA-based test
- One resistant animal had the genotype M307 A / G .
- 130 were M307 A / G or M307 G / G .
- the G-A changes at bp+307 and bp+857 of the alpha (1,2) fucosyltransferase gene 1 results in a predicted amino acid substitution of threonine (neutral-polar) instead of alanine (neutral-nonpolar) and glutamine (neutral-polar) instead of arginine (basic), respectively which may have functional consequences in the encoded product.
- a C-T change at bp 229 results in an amino acid substitution of leucine (neutral-nonpolar) instead of phenylalanine (neutral-nonpolar).
- Porcine genomic libraries were screened with either a porcine FUT1 probe obtained with primers P7 and P10 or a porcine FUT1 cDNA.
- a procine genomic library constructed in SuperCos 1 (Stragene, La Jolla, Ca, USA), was screened with an ⁇ 32 P dATP labeled (Prime It II, Stratagene) FUT1 probe obtained from procine genomic DNA with primers P7 and P10.
- After hybridization of replica filters at 42°C for 15h (50% formamide, 6 x SSC, 5 x Denhardt's, 0.5% SDS, 0.1 mg/ml Salmon Sperm) and washing twice at 65°C for 30 min. (1 x SSC, 0.1% SDS), positive colonies were identified after exposure (15h, -80°C) to X-ray film.
- Cosmid clones ETHs1, ETHs2, ETHs3, ETHs4 and ETHs6 were subjected to fluorescence in situ hybridization (FISH) (Solinas Toldo, et al. 1993) or direct in situ chromosomal PCT (DISC PCR) on porcine metaphases. Metaphase chromosomes were Q-banded and photographed before hybridization. The probes were labeled by random priming using biotin-16-dUTP. Signal detection and amplification was performed using avidin-FITC and biotinylated anti-avidin. The chromosomes were counterstained with 4,6-diamidino-2-phenylindole, and the relative positions of the cosmids were determined as described by Solinas Toldo, 1993.
- FISH fluorescence in situ hybridization
- DISC PCR direct in situ chromosomal PCT
- KspI-, EcoRI- and KspI/EcoRI digests of all cosmids were separated on a 0.8% agarose gel and transferred to a Hybond N nylon membrane (Meijerink et al ., 1997). This blot was hybridized with ⁇ 32 P dATP labeled porcine FUT1 PCR products (primers P6-P11 and P7-P10). Based on the autoradiographic signals, ETHs1, -s2 and -s3 were subjected to further subcloning into pBluescript SK- (Stratagene), and FUT sequences were determined from subclones.
- Haplotype frequencies were calculated from the parental animals, in the Landrace families and from the 8 parental Large White animals which were haplotyped for ECF18R from progeny information. Tetrachoric correlations of ECF18R and mutations in FUT1 ( FUT1 / M307 ) (polymorphisms) were calculated on all Landrace and Large White progeny.
- Southern blot analysis was performed of cosmids ETHs1, ETHs2 and ETHs3 after digestion with enzymes KspI, EcoRI and KspIEcoRI and separation of 0.8% agarose.
- Hybridization with an ⁇ 32 PdATP labeled 5' FUT1 fragment results in the same hybridizing 940 bp band in both the KspI digest and the KpsI/EcoRI digest.
- hybridization with a 3' FUT1 fragment (primers P7-P10) (Meijerink et al ., 1997) shows a 6.2 kb KspI band and a 1.1 kb KspI/EcoRI band.
- Both the 5' and 3' FUT1 fragments hybridize to the same 4.6 kb EcoRI fragment. This indicates the presence of a KspI site in the FUT1 gene contained in cosmid ETHs2.
- Cross hybridization of the 3' FUT1 fragment detects 2.7 kb and 8.2 kb bands, resulting in the identification of the FUT2 pseudogene (incomplete ORF) and the FUT2 gene sequences, respectively.
- Detection of (A) the M307 G to A and (B) the M857 G to A mutation in the porcine FUT1 gene was achieved by restriction length polymorphism analysis, using various restriction enzymes. Digestion of amplified FUT1 fragments with CfoI (A) and AciI (B) results in a restriction fragment polymorphism (Meijerink et al ., 1997).
- A) The M307 A / A genotype generates 328 and 93 bp restriction fragments while the M307 G / G genotype generates 93, 241 and 87 bp fragments and heterozygous M307 A / G genotypes shows all four fragments.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03001366A EP1310570B1 (en) | 1997-05-20 | 1998-05-20 | Methods and compositions to identify swine genetically resistant to F18 E. Coli associated diseases |
| DE29824744U DE29824744U1 (de) | 1997-05-20 | 1998-05-20 | Zusammensetzungen zur Identifizierung von Schweinen, die genetisch gegen F18 E. Coli-assoziierte Krankheiten resistent sind |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4718197P | 1997-05-20 | 1997-05-20 | |
| US471811P | 1997-05-20 | ||
| US47181P | 1997-05-20 | ||
| PCT/US1998/010318 WO1998053102A1 (en) | 1997-05-20 | 1998-05-20 | Methods and compositions to identify swine genetically resistant to f18 e. coli associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03001366A Division EP1310570B1 (en) | 1997-05-20 | 1998-05-20 | Methods and compositions to identify swine genetically resistant to F18 E. Coli associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0985052A1 EP0985052A1 (en) | 2000-03-15 |
| EP0985052B1 true EP0985052B1 (en) | 2003-08-06 |
Family
ID=21947500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98923570A Expired - Lifetime EP0985052B1 (en) | 1997-05-20 | 1998-05-20 | Methods and compositions to identify swine genetically resistant to f18 e. coli associated diseases |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6596923B1 (enExample) |
| EP (1) | EP0985052B1 (enExample) |
| JP (2) | JP3637420B2 (enExample) |
| CN (1) | CN1314953A (enExample) |
| AT (2) | ATE309392T1 (enExample) |
| AU (2) | AU7580798A (enExample) |
| BR (1) | BR9809137A (enExample) |
| CA (1) | CA2290768C (enExample) |
| CZ (1) | CZ298021B6 (enExample) |
| DE (3) | DE69832306T2 (enExample) |
| DK (2) | DK0985052T3 (enExample) |
| ES (2) | ES2203958T3 (enExample) |
| HK (1) | HK1040097A1 (enExample) |
| HU (1) | HUP0103587A3 (enExample) |
| MX (1) | MXPA99011988A (enExample) |
| NO (1) | NO996373L (enExample) |
| NZ (1) | NZ501886A (enExample) |
| PL (1) | PL195890B1 (enExample) |
| PT (1) | PT985052E (enExample) |
| RU (1) | RU2204609C2 (enExample) |
| WO (2) | WO1998053102A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2204609C2 (ru) * | 1997-05-20 | 2003-05-20 | Биотехнолоджи Резёрч Энд Девелопмент Корпорэйшен | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 |
| US6355859B1 (en) * | 1997-05-20 | 2002-03-12 | Biotechnology Research And Development Corporation | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease |
| HU221664B1 (hu) * | 1999-03-31 | 2002-12-28 | MTA Állatorvostudományi Kutatóintézete | Élő, szájon át adható Escherichia coli vakcina készítésére alkalmas törzs a sertések választási hasmenésének megelőzésére és a törzs előállítására alkalmas eljárás |
| GB0118549D0 (en) * | 2001-07-30 | 2001-09-19 | Pig Improvement Uk Ltd | Methods |
| US7785778B2 (en) | 2002-11-25 | 2010-08-31 | University Of Copenhagen | Porcine polymorphisms and methods for detecting them |
| BR0317329A (pt) | 2002-12-31 | 2005-11-08 | Mmi Genomics Inc | Composições, métodos e sistemas para inferir traços bovinos |
| CN104982387B (zh) * | 2015-05-25 | 2018-01-23 | 广东温氏食品集团股份有限公司 | 一种muc13和fut1基因的分子标记辅助选择方法 |
| CN108348585B (zh) * | 2015-09-02 | 2023-12-15 | 杜邦营养生物科学有限公司 | 糖苷水解酶及其在预防和/或治疗动物中的病原体感染中的用途 |
| CN106480174B (zh) * | 2016-09-14 | 2019-04-16 | 扬州大学 | 一种用于猪抗病育种的遗传分子标记方法和应用 |
| CN108384865A (zh) * | 2018-02-07 | 2018-08-10 | 扬州大学 | Alpha菌毛基因在仔猪腹泻致病性大肠杆菌监测、鉴别中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK41885A (da) | 1985-01-31 | 1986-11-13 | Slagteriernes Forskningsinst | 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen |
| EP0563144B2 (en) | 1990-12-21 | 2003-02-19 | The University Of Toronto Innovations Foundation | Diagnosis for porcine malignant hyperthermia |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5552144A (en) | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| AU5715194A (en) | 1992-12-04 | 1994-07-04 | N.V. Innogenetics S.A. | New polypeptides, nucleic acid sequences encoding them, and their use to prevent the adhesion of f107-fimbriated bacteria |
| US5625124A (en) * | 1994-07-11 | 1997-04-29 | Washington University | Animal model for helicobacter pylori infection |
| WO1996028967A1 (en) | 1995-03-17 | 1996-09-26 | Chihiro Koike | Transgenic non-primatal mammals wherein serotypes of higher primates have been expressed by foreign gene transfer and method of creating the same |
| RU2204609C2 (ru) * | 1997-05-20 | 2003-05-20 | Биотехнолоджи Резёрч Энд Девелопмент Корпорэйшен | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 |
| US6355859B1 (en) * | 1997-05-20 | 2002-03-12 | Biotechnology Research And Development Corporation | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease |
| US6569923B1 (en) * | 1999-03-19 | 2003-05-27 | John T. Slagter | Polymer-cement composites and methods of making same |
-
1998
- 1998-05-20 RU RU99127287/13A patent/RU2204609C2/ru not_active IP Right Cessation
- 1998-05-20 JP JP55057998A patent/JP3637420B2/ja not_active Expired - Fee Related
- 1998-05-20 HU HU0103587A patent/HUP0103587A3/hu unknown
- 1998-05-20 AT AT03001366T patent/ATE309392T1/de not_active IP Right Cessation
- 1998-05-20 HK HK02101688.3A patent/HK1040097A1/zh unknown
- 1998-05-20 DE DE69832306T patent/DE69832306T2/de not_active Expired - Fee Related
- 1998-05-20 CN CN98807387A patent/CN1314953A/zh active Pending
- 1998-05-20 MX MXPA99011988A patent/MXPA99011988A/es active IP Right Grant
- 1998-05-20 PT PT98923570T patent/PT985052E/pt unknown
- 1998-05-20 AU AU75807/98A patent/AU7580798A/en not_active Withdrawn
- 1998-05-20 CA CA002290768A patent/CA2290768C/en not_active Expired - Lifetime
- 1998-05-20 DK DK98923570T patent/DK0985052T3/da active
- 1998-05-20 WO PCT/US1998/010318 patent/WO1998053102A1/en not_active Ceased
- 1998-05-20 AU AU75832/98A patent/AU737862B2/en not_active Ceased
- 1998-05-20 EP EP98923570A patent/EP0985052B1/en not_active Expired - Lifetime
- 1998-05-20 WO PCT/US1998/010259 patent/WO1998053101A2/en not_active Ceased
- 1998-05-20 BR BR9809137-9A patent/BR9809137A/pt not_active Application Discontinuation
- 1998-05-20 ES ES98923570T patent/ES2203958T3/es not_active Expired - Lifetime
- 1998-05-20 ES ES03001366T patent/ES2248647T3/es not_active Expired - Lifetime
- 1998-05-20 PL PL98364701A patent/PL195890B1/pl unknown
- 1998-05-20 AT AT98923570T patent/ATE246731T1/de not_active IP Right Cessation
- 1998-05-20 CZ CZ0460799A patent/CZ298021B6/cs not_active IP Right Cessation
- 1998-05-20 NZ NZ501886A patent/NZ501886A/en unknown
- 1998-05-20 DE DE69816987T patent/DE69816987T2/de not_active Expired - Fee Related
- 1998-05-20 DE DE0985052T patent/DE985052T1/de active Pending
- 1998-05-20 DK DK03001366T patent/DK1310570T3/da active
-
1999
- 1999-11-19 US US09/443,766 patent/US6596923B1/en not_active Expired - Lifetime
- 1999-12-21 NO NO996373A patent/NO996373L/no unknown
-
2001
- 2001-04-27 US US09/844,705 patent/US6965022B2/en not_active Expired - Lifetime
- 2001-07-25 US US09/844,268 patent/US7193072B2/en not_active Expired - Fee Related
-
2004
- 2004-10-13 JP JP2004299458A patent/JP3941956B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meijerink et al. | Two α (1, 2) fucosyltransferase genes on porcine chromosome 6q11 are closely linked to the blood group inhibitor (S) and Escherichia coli F18 receptor (ECF18R) loci | |
| EP1565572B1 (en) | Porcine polymorphisms associated with resistance to enterotoxigenic e. coli and methods for detecting them | |
| EP0985052B1 (en) | Methods and compositions to identify swine genetically resistant to f18 e. coli associated diseases | |
| US6355859B1 (en) | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease | |
| JP4130125B2 (ja) | 牛における複合脊椎奇形キャリアーを同定するための遺伝試験 | |
| EP1310570B1 (en) | Methods and compositions to identify swine genetically resistant to F18 E. Coli associated diseases | |
| Cohney | HOSvyOrth et al. | |
| KR100432588B1 (ko) | 돼지 설사병 저항성 유전자 검정방법 | |
| Ridpath et al. | HOSvyOrth et al. | |
| Merrell et al. | Genetic analyses of tattered, an X-linked dominant, developmental mouse mutation | |
| Bosworth et al. | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19991220 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: RO PAYMENT 19991220 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| RTI1 | Title (correction) |
Free format text: METHODS AND COMPOSITIONS TO IDENTIFY SWINE GENETICALLY RESISTANT TO F18 E. COLI ASSOCIATED DISEASES |
|
| EL | Fr: translation of claims filed | ||
| TCNL | Nl: translation of patent claims filed | ||
| DET | De: translation of patent claims | ||
| 17Q | First examination report despatched |
Effective date: 20020118 |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VOEGELI, PETER Inventor name: BOSWORTH, BRAD, T. |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SWISS FEDERAL INSTITUTE OF TECHNOLOGY ZURICH Owner name: THE UNITED STATES OF AMERICA, REPRESENTED BY THE S Owner name: BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Extension state: RO |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030806 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030806 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030806 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 69816987 Country of ref document: DE Date of ref document: 20030911 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031106 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: RIEDERER HASLER & PARTNER PATENTANWAELTE AG |
|
| RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SWISS FEDERAL INSTITUTE OF TECHNOLOGY ZURICH Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE Owner name: BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PD4A Free format text: U.S.A.,AS REPRES. BY THE SECRETARY OF AGRICULTURE US Effective date: 20031205 |
|
| NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2203958 Country of ref document: ES Kind code of ref document: T3 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040520 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040520 |
|
| ET | Fr: translation filed | ||
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20040507 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060531 Year of fee payment: 9 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20070521 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20070528 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20070529 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20070530 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20070531 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20070615 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070702 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20070525 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: RITSCHER & PARTNER AG;RESIRAIN 1;8125 ZOLLIKERBERG (CH) |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20070517 Year of fee payment: 10 |
|
| BERE | Be: lapsed |
Owner name: SWISS *FEDERAL INSTITUTE OF TECHNOLOGY ZURICH Effective date: 20080531 Owner name: THE *UNITED STATES OF AMERICA AS REPRESENTED BY TH Effective date: 20080531 Owner name: *BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORP. Effective date: 20080531 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20081120 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20080520 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081120 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090119 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080602 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080531 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081202 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080520 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20080521 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070520 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080521 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080521 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20100524 Year of fee payment: 13 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20111201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111201 |